TY - JOUR
T1 - TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118
AU - Oh, J.
AU - Diaz, T.
AU - Wei, B.
AU - Chang, H.
AU - Noda, M.
AU - Stetler-Stevenson, W. G.
N1 - Funding Information:
We thank Hisataka Sabe (Osaka Bioscience Institute, Japan) for pBabe paxillin and pBabe paxillin (2X). This work was supported by intramural research funds from the National Cancer Institute, Center for Cancer Research (Project # Z01SC 009179).
PY - 2006/7/13
Y1 - 2006/7/13
N2 - We previously demonstrated that TIMP-2 increases the association of Crk with C3G and via subsequent activation of Rap1 enhances the expression of RECK, a membrane-anchored MMP inhibitor. In the present study, we investigate the mechanism of how the TIMP-2 signal is transduced from the α3β1 integrin receptor to the Crk-C3G-Rap1 molecular complex. TIMP-2 treatment of human microvascular endothelial cells (hMVECs) increased the phosphorylation levels of Src at Tyr-527, the negative regulatory site, through enhanced association of Src with Csk. This results in the reduction of Src kinase activity and dephosphorylation of paxillin at Tyr-31/118, the target sites for Src kinase phosphorylation and also the binding sites for the downstream effector Crk. Such TIMP-2 effects accompany the disassembly of paxillin-Crk-DOCK180 molecular complex and, in turn, Rac1 inactivation. On the contrary, levels of paxillin-Crk-C3G complex formation are not reduced, rather slightly increased, which is consistent with our previous finding. Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression.
AB - We previously demonstrated that TIMP-2 increases the association of Crk with C3G and via subsequent activation of Rap1 enhances the expression of RECK, a membrane-anchored MMP inhibitor. In the present study, we investigate the mechanism of how the TIMP-2 signal is transduced from the α3β1 integrin receptor to the Crk-C3G-Rap1 molecular complex. TIMP-2 treatment of human microvascular endothelial cells (hMVECs) increased the phosphorylation levels of Src at Tyr-527, the negative regulatory site, through enhanced association of Src with Csk. This results in the reduction of Src kinase activity and dephosphorylation of paxillin at Tyr-31/118, the target sites for Src kinase phosphorylation and also the binding sites for the downstream effector Crk. Such TIMP-2 effects accompany the disassembly of paxillin-Crk-DOCK180 molecular complex and, in turn, Rac1 inactivation. On the contrary, levels of paxillin-Crk-C3G complex formation are not reduced, rather slightly increased, which is consistent with our previous finding. Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression.
KW - Paxillin
KW - RECK
KW - Rac1
KW - Src
KW - TIMP-2
UR - http://www.scopus.com/inward/record.url?scp=33646831912&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1209444
DO - 10.1038/sj.onc.1209444
M3 - Article
C2 - 16491114
AN - SCOPUS:33646831912
SN - 0950-9232
VL - 25
SP - 4230
EP - 4234
JO - Oncogene
JF - Oncogene
IS - 30
ER -